RxDoctor Payments Data

Ahmed Farooq, MD

Infectious Disease · Venice, FLNPI 1811021769

Payments from drug & device makers

$471in general payments, 2019–2025

Across 26 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$210
  • Boston Scientific$54
  • Melinta Therapeutics, LLC$49
  • Gilead$40
  • Tetraphase Pharmaceuticals, Inc.$30
  • Merck$28
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$38381%
  • Education$8819%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$471 in reported general payments places this provider in the 40th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$756,400
Medicare patients
1,514
Services billed
6,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala56$228,790
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$130,092
Daptomycin67$62,068
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam189$44,355
Vancomycin Hcl213$32,298
ErtapenemErtapenem Sodium57$24,980
TivicayDolutegravir Sodium11$24,335
IsentressRaltegravir Potassium11$22,467
Cefepime Hcl87$20,222
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium25$17,297
Aztreonam14$17,098
Meropenem79$14,764
CeftriaxoneCeftriaxone Sodium141$9,220
Dicloxacillin Sodium38$8,136
Doxycycline Hyclate185$8,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$40$358,88281 claims
Viiv Healthcare CompanyTivicay$11$24,33511 claims
MerckIsentress$28$22,46711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →